Anti-PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care.

about

E2F1, a Novel Regulator of Metabolism.Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting.[Antibodies as treatment option in older adults].Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs.

P2860

Q47119185-2793D2B3-91AE-48F1-9016-FCC2CF91491E Q48311790-A339F5AE-4F54-403A-B5EF-66F115DB1DE5 Q48372695-B32B40C3-39B9-4B0E-A485-9F29B7BF5110 Q48526234-D5427784-E5C7-40B8-9EFD-EE18982324E0

P2860

Anti-PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care.

Item

http://www.wikidata.org/entity/Q38657213

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Anti-PCSK9 antibodies for hype ...... implications for primary care.

@en

type

Item

label

Anti-PCSK9 antibodies for hype ...... implications for primary care.

@en

prefLabel

Anti-PCSK9 antibodies for hype ...... implications for primary care.

@en

P1476

Anti-PCSK9 antibodies for hype ...... implications for primary care.

@en

P2093

Ioanna Gouni-Berthold

http://www.w3.org/2001/XMLSchema#string

Olivier S Descamps

http://www.w3.org/2001/XMLSchema#string

Ricardo Dent

http://www.w3.org/2001/XMLSchema#string

Uwe Fraass

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

How do we improve patient compliance and adherence to long-term statin therapy?

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

LDL-Cholesterol: Standards of Treatment 2016: A German Perspective.

Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data.

Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab: Pooled Data From Randomized Trials.

Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitm

Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering.

Safety of statins: an update

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

P31

scholarly article

review article

P356

10.1111/IJCP.12979

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Winfried März

P5008

ScienceSource

P577

2017-07-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2017-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28750477

http://www.w3.org/2001/XMLSchema#string

P921

P932

5601297

http://www.w3.org/2001/XMLSchema#string

Anti-PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care.

about

P2860

P2860

Anti-PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care.

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P31

P356

P433

P478

P50

P5008

P577

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P31

P356

P433

P478

P50

P5008

P577

P698

P921

P932